These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 9835523)

  • 1. An Escherichia coli expression assay and screen for human immunodeficiency virus protease variants with decreased susceptibility to indinavir.
    Melnick L; Yang SS; Rossi R; Zepp C; Heefner D
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3256-65. PubMed ID: 9835523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site.
    Mahalingam B; Wang YF; Boross PI; Tozser J; Louis JM; Harrison RW; Weber IT
    Eur J Biochem; 2004 Apr; 271(8):1516-24. PubMed ID: 15066177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid phenotypic assay for human immunodeficiency virus type 1 protease using in vitro translation.
    Iga M; Matsuda Z; Okayama A; Sugiura W; Hashida S; Morishita K; Nagai Y; Tsubouchi H
    J Virol Methods; 2002 Oct; 106(1):25-37. PubMed ID: 12367727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity.
    Schock HB; Garsky VM; Kuo LC
    J Biol Chem; 1996 Dec; 271(50):31957-63. PubMed ID: 8943242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in Brazil.
    Tanuri A; Vicente AC; Otsuki K; Ramos CA; Ferreira OC; Schechter M; Janini LM; Pieniazek D; Rayfield MA
    Antimicrob Agents Chemother; 1999 Feb; 43(2):253-8. PubMed ID: 9925514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials.
    Chen Z; Li Y; Schock HB; Hall D; Chen E; Kuo LC
    J Biol Chem; 1995 Sep; 270(37):21433-6. PubMed ID: 7665551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors.
    Maschera B; Furfine E; Blair ED
    J Virol; 1995 Sep; 69(9):5431-6. PubMed ID: 7636988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence of protease inhibitor resistance mutations in human immunodeficiency virus type 1 isolates from patients and rapid screening procedure for their detection.
    Vasudevachari MB; Zhang YM; Imamichi H; Imamichi T; Falloon J; Salzman NP
    Antimicrob Agents Chemother; 1996 Nov; 40(11):2535-41. PubMed ID: 8913459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor.
    Condra JH; Holder DJ; Schleif WA; Blahy OM; Danovich RM; Gabryelski LJ; Graham DJ; Laird D; Quintero JC; Rhodes A; Robbins HL; Roth E; Shivaprakash M; Yang T; Chodakewitz JA; Deutsch PJ; Leavitt RY; Massari FE; Mellors JW; Squires KE; Steigbigel RT; Teppler H; Emini EA
    J Virol; 1996 Dec; 70(12):8270-6. PubMed ID: 8970946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the protease sequences of HIV-1 infected individuals after Indinavir monotherapy.
    Sa-Filho DJ; Costa LJ; de Oliveira CF; Guimarães AP; Accetturi CA; Tanuri A; Diaz RS
    J Clin Virol; 2003 Oct; 28(2):186-202. PubMed ID: 12957189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors.
    Rusconi S; La Seta Catamancio S; Citterio P; Kurtagic S; Violin M; Balotta C; Moroni M; Galli M; d'Arminio-Monforte A
    Antimicrob Agents Chemother; 2000 May; 44(5):1328-32. PubMed ID: 10770770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.
    Turner D; Schapiro JM; Brenner BG; Wainberg MA
    Antivir Ther; 2004 Jun; 9(3):301-14. PubMed ID: 15259893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy.
    Servais J; Lambert C; Fontaine E; Plesséria JM; Robert I; Arendt V; Staub T; Schneider F; Hemmer R; Burtonboy G; Schmit JC
    J Clin Microbiol; 2001 Feb; 39(2):454-9. PubMed ID: 11158089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence of mutations during replication of an HIV library containing combinations of selected protease mutations.
    Song W; Maeda Y; Tenpaku A; Harada S; Yusa K
    Antiviral Res; 2004 Mar; 61(3):173-80. PubMed ID: 15168798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological characterization of human immunodeficiency virus type 1 subtype C protease carrying indinavir drug-resistance mutations.
    Gonzalez LMF; Aguiar RS; Afonso A; Brindeiro PA; Arruda MB; Soares MA; Brindeiro RM; Tanuri A
    J Gen Virol; 2006 May; 87(Pt 5):1303-1309. PubMed ID: 16603533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations between amino acids in the evolution of HIV type 1 protease sequences under indinavir therapy.
    Brown AJ; Korber BT; Condra JH
    AIDS Res Hum Retroviruses; 1999 Feb; 15(3):247-53. PubMed ID: 10052755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indinavir resistance evolution in one human immunodeficiency virus type 1 infected patient revealed by single-genome amplification.
    Geng QM; Li HP; Bao ZY; Liu YJ; Zhuang DM; Li L; Liu SY; Li JY
    Virol Sin; 2010 Oct; 25(5):316-28. PubMed ID: 20960178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants.
    Martinez-Picado J; Savara AV; Shi L; Sutton L; D'Aquila RT
    Virology; 2000 Sep; 275(2):318-22. PubMed ID: 10998332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.
    Côté HC; Brumme ZL; Harrigan PR
    J Virol; 2001 Jan; 75(2):589-94. PubMed ID: 11134271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites.
    Zhang YM; Imamichi H; Imamichi T; Lane HC; Falloon J; Vasudevachari MB; Salzman NP
    J Virol; 1997 Sep; 71(9):6662-70. PubMed ID: 9261388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.